| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2020: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2019: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
We present the first systematic study of the inhibitory effects of palmitoyl piperidinopiperidine, abbreviated as PPI (Japan Patent No. 5597427), on the colon carcinogenesis. Our investigation demonstrate (1) specific cancer cell killing activity, (2) induction of apoptosis of cancer cells, (3) inhibition of angiogenesis, (4) growth inhibition of implanted cancer cells, (5) suppression of the promotion of colon carcinogenesis, (6) inhibition of transcriptional activity of the transcription factor STAT3 by blocking the dimerization of STAT3. These novel effects of PPI provide further evidence that PPI may be a valuable lead compound in the prevention and therapy of colon cancer and possibly other gastrointestinal cancer.
|
